抗血管内皮生长因子药物玻璃体内注射相关的不良反应和并发症：文献复习。
Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature.
机构信息
Department of Ophthalmology, Eye Research Center, Rassoul Akram Hospital, Tehran University of Medical Sciences, Tehran, Iran.
出版信息
Eye (Lond). 2013 Jul;27(7):787-94. doi: 10.1038/eye.2013.107. Epub 2013 May 31.
Abstract
Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly used for the treatment of a wide variety of retinal diseases, including age-related macular degeneration, diabetic retinopathy and retinal vascular occlusions, and retinopathy of prematurity. Despite encouraging results in halting the disease and improving the vision, intravitreal injection of anti-VEGF agents may be associated with systemic adverse events and devastating ocular complications. In this review, we provide an overview of safety data for intravitreal injection of common anti-VEGF agents.
摘要
玻璃体内注射抗血管内皮生长因子 (VEGF) 药物越来越多地用于治疗各种视网膜疾病，包括年龄相关性黄斑变性、糖尿病性视网膜病变和视网膜血管阻塞以及早产儿视网膜病变。尽管在阻止疾病和改善视力方面取得了令人鼓舞的结果，但玻璃体内注射抗 VEGF 药物可能与全身不良事件和严重的眼部并发症有关。在这篇综述中，我们提供了常见抗 VEGF 药物玻璃体内注射的安全性数据概述。
相似文献
1
Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature.抗血管内皮生长因子药物玻璃体内注射相关的不良反应和并发症：文献复习。
Eye (Lond). 2013 Jul;27(7):787-94. doi: 10.1038/eye.2013.107. Epub 2013 May 31.
2
The role of antibiotics in the prevention of post-intravitreal anti-VEGF endophthalmitis: primum non nocere!抗生素在预防玻璃体内注射抗VEGF药物后眼内炎中的作用：首要原则是不伤害！
Eye (Lond). 2014 Apr;28(4):500. doi: 10.1038/eye.2013.309. Epub 2014 Jan 10.
3
The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.血管内皮生长因子抑制剂在眼科中的作用不断扩大。
Mayo Clin Proc. 2012 Jan;87(1):77-88. doi: 10.1016/j.mayocp.2011.10.001.
4
Complications of intravitreal injections in patients with diabetes.糖尿病患者玻璃体内注射的并发症
Semin Ophthalmol. 2014 Sep-Nov;29(5-6):276-89. doi: 10.3109/08820538.2014.962167.
5
Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.玻璃体内抗血管内皮生长因子单克隆抗体相关的心血管事件和出血风险：系统评价与荟萃分析
JAMA Ophthalmol. 2014 Nov;132(11):1317-26. doi: 10.1001/jamaophthalmol.2014.2333.
6
Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.抗血管内皮生长因子治疗视网膜分支静脉阻塞继发的黄斑水肿。
Cochrane Database Syst Rev. 2013 Jan 31(1):CD009510. doi: 10.1002/14651858.CD009510.pub2.
7
Reply to Dr Grzybowski.致格日博夫斯基博士的回复。
Eye (Lond). 2014 Apr;28(4):501. doi: 10.1038/eye.2013.302. Epub 2014 Jan 10.
8
[Complications of intravitreal injections--own experience].[玻璃体内注射的并发症——自身经验]
Klin Oczna. 2011;113(4-6):127-31.
9
Adverse gastrointestinal events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study.玻璃体内注射血管内皮生长因子抑制剂的不良胃肠道事件：巢式病例对照研究。
Drug Saf. 2014 Sep;37(9):723-33. doi: 10.1007/s40264-014-0211-6.
10
Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study.玻璃体内注射抗血管内皮生长因子药物治疗不同眼部疾病后的局部和全身并发症：一项五年回顾性研究
Semin Ophthalmol. 2015 Mar;30(2):129-35. doi: 10.3109/08820538.2013.835833. Epub 2013 Oct 30.
引用本文的文献
1
Ultrasound Biomicroscopy of Patients With Hemorrhagic Complications Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection.玻璃体内注射抗血管内皮生长因子后出血性并发症患者的超声生物显微镜检查
J Vitreoretin Dis. 2025 Aug 28:24741264251364011. doi: 10.1177/24741264251364011.
2
Evaluation of pain scores during intravitreal injection in systemic conditions and in conjunction with medications.全身性疾病及联合用药情况下玻璃体内注射时疼痛评分的评估。
Ther Adv Ophthalmol. 2025 Aug 24;17:25158414241275360. doi: 10.1177/25158414241275360. eCollection 2025 Jan-Dec.
3
A Comparative Assessment of Intraocular Pressure Changes After Aflibercept 8 mg and Faricimab-svoa Intravitreal Injections in Wet Age-Related Macular Degeneration.阿柏西普8毫克与法西单抗-svoa玻璃体内注射治疗湿性年龄相关性黄斑变性后眼压变化的比较评估
Cureus. 2025 Jul 23;17(7):e88617. doi: 10.7759/cureus.88617. eCollection 2025 Jul.
4
Pars plana vitrectomy with ILM peeling for macular edema of various etiologies: results from the SCRV macula surgery study.采用内界膜剥除术的玻璃体切除术治疗各种病因引起的黄斑水肿：SCRV黄斑手术研究结果
Int Ophthalmol. 2025 Aug 25;45(1):352. doi: 10.1007/s10792-025-03721-0.
5
Mathematical Models of Topically and Intravitreally Applied Ranibizumab.玻璃体内及局部应用雷珠单抗的数学模型
Invest Ophthalmol Vis Sci. 2025 Aug 1;66(11):45. doi: 10.1167/iovs.66.11.45.
6
Management and safety of same day bilateral intravitreal anti-VEGF injections in a treat-and-extend regimen.治疗-延长方案中同一天双侧玻璃体内抗VEGF注射的管理与安全性
BMC Ophthalmol. 2025 Aug 14;25(1):459. doi: 10.1186/s12886-025-04293-4.
7
A Novel, Long-Acting, Small Molecule PKM2 Activator and Its Potential Broad Application Against Photoreceptor Degeneration.一种新型长效小分子丙酮酸激酶M2激活剂及其在对抗光感受器变性方面的潜在广泛应用。
Transl Vis Sci Technol. 2025 Jul 1;14(7):26. doi: 10.1167/tvst.14.7.26.
8
Topical ophthalmic administration of the antiangiogenic peptide VIAN-c4551 protects against experimental diabetic macular edema.抗血管生成肽VIAN-c4551的局部眼内给药可预防实验性糖尿病性黄斑水肿。
Sci Rep. 2025 Jul 23;15(1):26767. doi: 10.1038/s41598-025-12331-w.
9
Bone morphogenetic proteins (BMPs) at the forefront of ocular diseases and therapeutics.骨形态发生蛋白（BMPs）在眼部疾病与治疗领域处于前沿地位。
Eye Vis (Lond). 2025 Jul 23;12(1):29. doi: 10.1186/s40662-025-00445-1.
10
Inorganic nanomaterials as promising therapeutic agents for ocular neovascularization: Progress and perspectives.无机纳米材料作为治疗眼部新生血管的有前景的治疗剂：进展与展望
Mater Today Bio. 2025 Jul 4;33:102051. doi: 10.1016/j.mtbio.2025.102051. eCollection 2025 Aug.
本文引用的文献
1
Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a single clinical center.单中心玻璃体腔注射贝伐单抗后急性眼内炎的发生率。
Retina. 2013 May;33(5):971-4. doi: 10.1097/IAE.0b013e31826f0675.
2
A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard.贝伐单抗和雷珠单抗的安全性回顾和荟萃分析：超适应证与金标准。
PLoS One. 2012;7(8):e42701. doi: 10.1371/journal.pone.0042701. Epub 2012 Aug 3.
3
Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity.早产儿视网膜病变 3 期玻璃体内注射贝伐单抗后迟发性非典型玻璃体视网膜牵引带形成。
Eye (Lond). 2012 Jul;26(7):903-9; quiz 910. doi: 10.1038/eye.2012.111. Epub 2012 Jun 15.
4
Successful management of choroidal metastasis with intravitreal ranibizumab injections.玻璃体内注射雷珠单抗成功治疗脉络膜转移瘤。
Ophthalmic Surg Lasers Imaging. 2012 May 24;43 Online:e47-51. doi: 10.3928/15428877-20120517-03.
5
Reactivation of retinopathy of prematurity after bevacizumab injection.注射贝伐单抗后早产儿视网膜病变复发。
Arch Ophthalmol. 2012 Aug;130(8):1000-6. doi: 10.1001/archophthalmol.2012.592.
6
Changes in antibiotic resistance patterns of conjunctival flora due to repeated use of topical antibiotics after intravitreal injection.眼内注射后反复使用局部抗生素导致结膜菌群耐药模式的变化。
Ophthalmology. 2012 Jul;119(7):1420-4. doi: 10.1016/j.ophtha.2012.01.016. Epub 2012 Mar 13.
7
Reducing oral flora contamination of intravitreal injections with face mask or silence.使用口罩或保持安静减少玻璃体腔内注射时的口腔菌群污染。
Retina. 2012 Mar;32(3):473-6. doi: 10.1097/IAE.0B013E31822C2958.
8
Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.雷珠单抗治疗糖尿病性黄斑水肿：两项 III 期随机临床试验（RISE 和 RIDE）的结果。
Ophthalmology. 2012 Apr;119(4):789-801. doi: 10.1016/j.ophtha.2011.12.039. Epub 2012 Feb 11.
9
An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab.玻璃体内注射贝伐单抗后发生内源性链球菌眼内炎。
Am J Ophthalmol. 2012 Feb;153(2):204-208.e1. doi: 10.1016/j.ajo.2011.11.035.
10
Avastin doesn't blind people, people blind people.阿瓦斯汀不会让人失明，是人让人为之失明。
Am J Ophthalmol. 2012 Feb;153(2):196-203.e1. doi: 10.1016/j.ajo.2011.11.023.
Zotero 插件